1.Effect of intravenous infusion of low-dose remifentanil on obese scarred uterine puerperae undergoing cesarean section under epidural anesthesia
Chang CHEN ; Chao LIU ; Guang-Le WEI ; Shu WANG ; Lin JI ; Ti-Jun DAI
Journal of Regional Anatomy and Operative Surgery 2024;33(11):945-949
Objective To investigate the effect of intravenous infusion of low-dose remifentanil on obese scarred uterine puerperae undergoing cesarean section under epidural anesthesia.Methods A total of 87 obese scarred uterine puerperae undergoing cesarean section under epidural anesthesia were selected as the study subjects,and they were randomly divided into the conventional group(n=43)and the remifentanil group(n=44).From the beginning of skin incision,puerperae of the conventional group and the remifentanil group were intravenously injected with normal saline and low-dose remifentanil respectively until the end of the operation.The vital signs,pain and comfort scores,intraoperative complications of puerperae,and status of newborns were compared between the two groups at different points during the operation.Results During fetal extraction and peritoneal exploration,the heart rate,mean arterial pressure and pain scores of puerperae in the remifentanil group were lower than those in the conventional group,and the differences were statistically significant(P<0.05);the intraoperative comfort score of puerperae in the remifentanil group was higher than that in the conventional group,and the difference was statistically significant(P<0.05).The incidence of nausea and vomiting of puerperae in the remifentanil group was lower than that in the conventional group,and the difference was statistically significant(P<0.05).There was no significant difference in the Apgar score at 1 minute and 5 minutes after delivery,requiring initial resuscitation or pH value of umbilical vein blood between newborns delivered by puerperae of the two groups(P>0.05).Conclusion Intravenous infusion of 0.05 μg·kg-1·min-1 low-dose remifentanil not only significantly reduces intraoperative pain and improves comfort of obese scarred uterine puerperae undergoing cesarean section under epidural anesthesia,but also helps to reduce the incidence of adverse reactions and ensure maternal and infant safety.
2. Treatment advice of small molecule antiviral drugs for elderly COVID-19
Min PAN ; Shuang CHANG ; Xiao-Xia FENG ; Guang-He FEI ; Jia-Bin LI ; Hua WANG ; Du-Juan XU ; Chang-Hui WANG ; Yan SUN ; Xiao-Yun FAN ; Tian-Jing ZHANG ; Wei WEI ; Ling-Ling ZHANG ; Jim LI ; Fei-Hu CHEN ; Xiao-Ming MENG ; Hong-Mei ZHAO ; Min DAI ; Yi XIANG ; Meng-Shu CAO ; Xiao-Yang CHEN ; Xian-Wei YE ; Xiao-Wen HU ; Ling JIANG ; Yong-Zhong WANG ; Hao LIU ; Hai-Tang XIE ; Ping FANG ; Zhen-Dong QIAN ; Chao TANG ; Gang YANG ; Xiao-Bao TENG ; Chao-Xia QIAN ; Guo-Zheng DING
Chinese Pharmacological Bulletin 2023;39(3):425-430
COVID-19 has been prevalent for three years. The virulence of SARS-CoV-2 is weaken as it mutates continuously. However, elderly patients, especially those with underlying diseases, are still at high risk of developing severe infections. With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2, antiviral drugs for COVID-19 have been successively marketed, and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients. This article reviews the mechanism, clinical medication regimens, drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China, so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.
3.Metabolic Disease Management Guideline for National Metabolic Management Center(2nd edition)
Weiqing WANG ; Yufan WANG ; Guixia WANG ; Guang NING ; Dalong ZHU ; Ping LIU ; Libin LIU ; Jianmin LIU ; Zhaoli YAN ; Xulei TANG ; Bangqun JI ; Sunjie YAN ; Heng SU ; Jianling DU ; Sheli LI ; Li LI ; Shengli WU ; Jinsong KUANG ; Yubo SHA ; Ping ZHANG ; Yifei ZHANG ; Lei CHEN ; Zunhai ZHOU ; Chao ZHENG ; Qidong ZHENG ; Zhongyan SHAN ; Dong ZHAO ; Zhigang ZHAO ; Ling HU ; Tingyu KE ; Yu SHI ; Yingfen QIN ; Mingjun GU ; Xuejiang GU ; Fengmei XU ; Zuhua GAO ; Qijuan DONG ; Yi SHU ; Yuancheng DAI
Chinese Journal of Endocrinology and Metabolism 2023;39(6):538-554
The latest epidemiological data suggests that the situation of adult diabetes in China is severe, and metabolic diseases have become significant chronic illnesses that have a serious impact on public health and social development. After more than six years of practice, the National Metabolic Management Center(MMC) has developed distinctive approaches to manage metabolic patients and has achieved a series of positive outcomes, continuously advancing the standardized diagnosis and treatment model. In order to further improve the efficiency, based on the first edition, the second edition guideline was composed by incorporating experience of the past six years in conjunction with the latest international and domestic guidelines.
4.Effect of Qingfei Xiegantang on Chronic Inflammation and Endothelial Function with Metabolic Syndrome
Cong-shu DAI ; Yu-bo GAO ; Guang-yao LI ; Jia-hao LIU ; Chang-qing LIN
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(5):105-110
Objective:To discuss the clinical efficacy of Qingfei Xiegantang on chronic inflammation and endothelial function of people of Taiyin constitution with metabolic syndrome (MS). Method:Patients (162 cases) were divided into control group (80 cases) and observation group (82 cases). Both groups got lifestyle intervention and treatment with lipid regulation, blood pressure reduction and hypoglycemia according to MS. Patients in observation group got Qingfei Xiegantang, 1 dose/day. Patients in control group got placebo granules of Qingfei Xiegantang. The treatment lasted for 4 months. Before and after treatment, weight, height, waist (WC), hip, body mass index (BMI) and waist hip ratio (WHR) were calculated. Levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), 2-hour postprandial blood glucose (2 hPG), glycosylated hemoglobin (HbA1c) and fasting insulin (FINS) were measured. Insulin resistance index (HOMA-IR), insulin sensitivity index (ISI) and islet beta cell function index (HOMA-
5.Dao-di herbs pharmacology and new ideas of Dao-di herbs standard construction.
Jun-Ning ZHAO ; Hua HUA ; Ying DAI ; Qing-Mao FANG ; Qing-Miao LI ; Shun-Yuan JIANG ; Chun-Guang XIE ; Si-Jin YANG ; Liang-Chun YAN ; Peng TAN ; An-Dong YANG ; Shu WANG
China Journal of Chinese Materia Medica 2020;45(4):709-714
Guided by the basic theory of traditional Chinese medicine and using modern scientific methods, Dao-di herbs pharmacology studies the nature, performance, interaction with the body and its clinical application.It is a bridge between the basic research and clinical application of Dao-di herbs. It can objectively describe the law of efficacy of Dao-di herbs, scientifically explain the mechanism of efficacy of Dao-di herbs, explore and establish the standards and methods of Dao-di herbs based on biological effect and clinical efficacy, and provide scientific basis for the special properties, pharmacology and clinical value of Dao-di herbs.Furthermore, we put forward a new idea of building the standard of Dao-di herbs based on the curative effect rather than the origin.The Dao-di herbs standard should come from the systematic research of traditional Dao-di herbs producing areas and form a new characteristic system, through the extraction of environmental, genetic, character, chemical, pharmacological and other characteristics.This standard originates from the tradition, but it is higher than the tradition. It may not have the origin meaning of strict administrative division, but it can better reflect the pharmacological characteristics and excellent clinical value of Dao-di herbs.
China
;
Drugs, Chinese Herbal/standards*
;
Medicine, Chinese Traditional
;
Plants, Medicinal/chemistry*
6. Regulatory Effect of Qingfei Xiegan Tang on Inflammatory Response and Intestinal Flora of Type 2 Diabetes Mellitus
Cong-shu DAI ; Zhuo YU ; Guang-yao LI ; Chang-qing LIN
Chinese Journal of Experimental Traditional Medical Formulae 2019;25(18):83-88
Objective: To observe the clinical efficacy of Chaoyi Qingfei Xiegan Tang on type 2 diabetes mellitus (T2DM), and the regulatory effect on inflammatory markers and intestinal flora. Method: One hundred and twenty-two patients were randomly divided into control group (65 cases) and observation group (67 cases) by random number table. Patients in control group got metformin hydrochloride, 0.25 g/time, 2-3 times/day, and the dose was regulated based on glycemic control. In addition to the therapy in control groups, patients in observation group were also given Qingfei Xiegan Tang, 1 dose/day. A course of treatment was 2 months. Before and after treatment, levels of fasting blood glucose (FPG), 2 h-postprandial plasma glucose (2 h PPG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HLD), low-density lipoprotein (LDL-C), interleukin-6 (IL-6), IL-8, tumor necrosis factor-α(TNF-α) and C-reactive protein (CRP) were detected. And insulin sensitivity index (ISI), HOMA insulin resistance index (HOMA-IR) and intestinal flora were detected. And scores of TCM symptoms were graded. Result: By rank sum test, the clinical efficacy of disease in observation group was better than that in control group (P<0.01). After treatment, levels of FPG, 2 h PG, HbA1c, FINS, HOMA-IR, TC, TG, LDL-C, IL-6, IL-8, TNF-α and CRP were lower than those in control group (P<0.01), and levels of ISI, HDL-C were higher than those in control group (P<0.01). And the number of intestinal aerobic bacteria (enterobacter, enterococcus and yeast) was less than that in control group (P<0.05), and intestinal anaerobic flora (bacteroides, bifidobacterium and lactobacillus) were higher than those in control group (P<0.05). Conclusion: Qingfei Xiegan Tang can ameliorate 2 h PG, regulate levels of glucose, lipid and intestinal flora, relieve clinical symptoms, and inhibit inflammatory response, with a better clinical efficacy than that of pure western medicine.
7.Research progress on risk assessment of drug-induced diseases in older adults
Guang-Yu YAN ; Yao LU ; Hai-Jiang DAI ; Jia WEN ; Jing-Xian SHU ; Na-Na XU ; Hong YUAN
The Chinese Journal of Clinical Pharmacology 2018;34(1):92-94
Drug-induced diseases (DIDs)are serious problems,resulting in huge social and economic burdens.Drugs with high rates of drug-induced disease in older adults are warfarin,insulin,oral antiplatelet agents,oral hypoglycemic agents,opioid analgesics and antineoplastic agents.To the drugs mentioned above,foreign progress of related research in risk assessments and early warning models has been made.Aiming to provide evidence for the prevention and control of drug-induced diseases in the elderly population,this review will briefly introduce the harm of DIDs,and review the research progress of the risk assessment model of common DIDs in older adults.
8.Analysis of coronary intramural hematomas after coronary artery stent implantation
Shu-Fu CHANG ; Jian-Ying MA ; Chen-Guang LI ; Yu-Xiang DAI ; Hao LU ; Feng ZHANG ; Kang YAO ; Yan YAN ; Bing FAN ; Qi-Bing WANG ; Ju-Ying QIAN ; Jun-Bo GE
Chinese Journal of Interventional Cardiology 2018;26(6):311-315
Objective To analyze the rates of occurrence,presentations and treatment of coronary intramural hematomas(IMH)after coronary artery stent implantation.Methods Retrospective analysis was carried out in non-chronic total occlusion patients who developed coronary intramural hematomas after coronary artery stent implantation between January 1,2011 to December 31,2016.Statistical analysis was made in the fields clinical data,coronary angiography features,treatment provided,and postoperative follow-up date of the patients.Results Among the 26 IMH patients,the male gender(15/26,57.7%)and existiing hypertension(17/26,65.4%)were more common risk factors for IMH after coronary artery stent implantation.Fourteen patients developed coronary dissection.The coronary intramural hematomas presented as new non-spasm and non-thrombus coronary stenosis.The coronary intramural hematomas were found to have involved the distal segment to the stents in 16 patients.Two patients received balloon dilation,five patients had stents implantation after balloon dilation,13 patients(50.0%)were treated with direct stent implantation and the other 6 patients did not have further intervention.The follow up period after hospital discharge was(2.39±1.68)years.No adverse cardiovascular event occurred.Five patients received follow-up angiography examination.Two patients and another one patient were found to have coronary intramural hematomas fully resolved at three months and one year with coronary angiographic follow up,respectively.Two patients had IMH on angiography at 1 year follow up.Conclusions Coronary intramural hematomas after coronary artery stent implantation often involved the distal segment to the stent in hypertensive patients presenting as new non-spasm and non-thrombus coronary stenosis.Patients at low risk of acute coronary occlusion could receive conservative treatment.Patients with extentsive length of intramural hematomas should consider stent implantation for treatment.
9.Staging Based Strategies and Practice for Prostate Cancer.
Zhi-qiang CHEN ; Shu-sheng WANG ; Zun-guang BAI ; Zhao-hui WANG ; Li-guo LV ; Chi-ming GU ; Song-tao XIANG ; Rui-xin DAI ; Shou-lun ZHU
Chinese Journal of Integrated Traditional and Western Medicine 2016;36(6):749-752
Authors raised that staging based strategies and practice of integrative medicine (IM) by combining syndrome typing and disease identification, and choosing suitable measures in accordance with different persons and seasonal conditions after more than ten years' clinical practice and researches. Radical operation as prior (as evil eliminating) and strengthening vital qi in perioerative period are best strategy for promoting rapid rehabilitation of early stage prostate cancer patients. Strengthening body resistance to eliminate evil was used in treating advanced prostate cancer patients. For example, a comprehensive treatment program for hormone-dependent patients was combined with endocrinotherapy and Chinese herbs for synergisic efficacy-enhancing actions. In this way, these patients' quality of life (QOL) were improved and time to castration resistant prostate cancer (CRPC) was delayed, even some patients were clinically cured. There are lack of effective medicines and methods for CRPC patients. Greatly tonifying original qi is mainly used for improving their clinical symptoms and prolonging survivals. Practice has proved staging based strategies and practice of IM has favorable advantages in treating prostate cancer, especially showing prospect in prolonging survival and postponing progression of advanced prostate cancer patients. Besides, it also could provide beneficial considerations and inspiration for combination of syndrome typing and disease identification.
Disease Progression
;
Humans
;
Male
;
Medicine, Chinese Traditional
;
Neoplasm Staging
;
Prostatic Neoplasms, Castration-Resistant
;
diagnosis
;
Quality of Life
10.Shenfu injection induces the apoptosis of prostate cancer PC-3 cells.
Li-Guo LÜ ; Xian ZHANG ; Zhi-Qiang CHEN ; Zun-Guang BAI ; Qiao-Ling WU ; Zhao-Hui WANG ; Rui-Xin DAI ; Xiu-Qiong ZHANG ; Si-Yi LI ; Shu-Sheng WANG
National Journal of Andrology 2014;20(6):539-543
OBJECTIVETo study the effect of Shenfu Injection (SF) on the apoptosis of prostate cancer PC-3 cells and its possible mechanism.
METHODSWe divided prostate cancer PC-3 cells into a blank control group and three experimental groups, the latter treated with SF at 50, 100, and 200 microl/ml, respectively, for 24, 48, and 72 hours. Then we determined the proliferation of the cells by MTT assay, measured their apoptosis by Annexin V/PI flow cytometry, and detected the expression of P53 mRNA by RT-qPCR.
RESULTSCompared with the blank control group, the survival rates of the prostate cancer PC-3 cells in the 50, 100, and 200 microl/ml SF groups were (93.76 +/- 2.63)%, (81.21 +/- 1.80)% and (18.01 +/- 3.84)% at 24 hours, (94.67 +/-1.11)%, (78.33 +/- 2.89)% and (10.34 +/- 1.44)% at48 hours, and (91.30 +/- 0.47)%, (36.67 +/- 1.56)% and (1.33 +/- 0.32)% at 72 hours, all significantly increased in a dose- and time-dependent manner (P < 0.05). The expression of p53 mRNA was also markedly increased in all the three experimental groups at 48 hours (P < 0. 05).
CONCLUSIONSF can inhibit the proliferation and induce the apoptosis of PC-3 cells, which may due to its upregulation of the p53 mRNA expression.
Apoptosis ; drug effects ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Drugs, Chinese Herbal ; pharmacology ; Humans ; Male ; Prostatic Neoplasms ; metabolism ; pathology ; Tumor Suppressor Protein p53 ; metabolism

Result Analysis
Print
Save
E-mail